Department of Laboratory Medicine and Pathology, Rochester, MN, USA.
Division of Medical Oncology, Department of Oncology, Rochester, MN, USA.
Am J Clin Pathol. 2021 Oct 13;156(5):853-865. doi: 10.1093/ajcp/aqab038.
To evaluate SATB2 expression and prognostic implications in a large cohort of thoracic neuroendocrine tumors.
Surgical pathology files (1995-2017) and an institutional thymic epithelial tumor database (2010-2020) were searched for resected neuroendocrine tumors. Cases were stained with SATB2 (clone EP281). Percent SATB2-positive tumor cells and expression intensity were scored.
In the lung, SATB2 was expressed in 5% or more of tumor cells in 29 (74.4%) of 39 small cell carcinomas and 9 (22.5%) of 40 atypical and 26 (40.6%) of 64 typical carcinoid tumors. SATB2 percent tumor cell expression and intensity were higher in small cell carcinomas than in carcinoid tumors (both P < .001, respectively). After adjusting for tumor subtype, SATB2 expression did not correlate with outcome. In the thymus, four (100%) of four atypical carcinoid tumors and one large cell neuroendocrine carcinoma but no small cell carcinoma (n = 2) expressed SATB2 in 5% or more of tumor cells.
SATB2 (clone EP281) is expressed in a large subset of pulmonary and thymic neuroendocrine tumors and therefore does not appear to be a useful marker to identify the origin of neuroendocrine tumors. Validation studies are needed, specifically including thymic neuroendocrine tumors, as the expression pattern might be different in those tumors.
评估 SATB2 在大型胸内神经内分泌肿瘤队列中的表达和预后意义。
检索 1995 年至 2017 年的外科病理学档案和机构胸内上皮性肿瘤数据库（2010 年至 2020 年），寻找切除的神经内分泌肿瘤病例。使用 SATB2（克隆 EP281）进行染色。对 SATB2 阳性肿瘤细胞的百分比和表达强度进行评分。
在肺部，SATB2 在 39 例小细胞癌中有 29 例（74.4%）或更多肿瘤细胞中表达，在 40 例非典型类癌中有 9 例（22.5%）和 26 例典型类癌中有 26 例（40.6%）表达。小细胞癌中 SATB2 的肿瘤细胞表达百分比和强度均高于类癌（均 P<0.001）。在调整肿瘤亚型后，SATB2 表达与预后无关。在胸腺中，4 例（100%）非典型类癌和 1 例大细胞神经内分泌癌中有 SATB2 在 5%或更多肿瘤细胞中表达，但没有小细胞癌（n=2）。
SATB2（克隆 EP281）在一大类肺和胸腺神经内分泌肿瘤中表达，因此似乎不是识别神经内分泌肿瘤起源的有用标志物。需要进行验证研究，特别是包括胸腺神经内分泌肿瘤，因为这些肿瘤的表达模式可能不同。
